US Patent Issued to BETA PHARMA on April 7 for "Crystalline and amorphous forms of N-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof" (Pennsylvania, Wisconsin, New Jersey Inventors)

ALEXANDRIA, Va., April 7 -- United States Patent no. 12,595,246, issued on April 7, was assigned to BETA PHARMA INC. (Wilmington, Del.).

"Crystalline and amorphous forms of N-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof" was invented by Michael Nicholas Greco (Lanesdale, Pa.), Michael John Costanzo (Warminster, Pa.), Jirong Peng (Mequon, Wis.) and Don Zhang (Princeton, N.J.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Crystalline and amorphous forms of N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl-5-fluoro-4-(3-iso-propyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-amine (C...